Douglas Lane & Associates LLC cut its stake in Illumina, Inc. (NASDAQ:ILMN) by 0.5% during the first quarter, Holdings Channel reports. The fund owned 484,567 shares of the life sciences company’s stock after selling 2,623 shares during the period. Illumina accounts for approximately 2.1% of Douglas Lane & Associates LLC’s holdings, making the stock its 3rd largest position. Douglas Lane & Associates LLC owned approximately 0.33% of Illumina worth $82,687,000 as of its most recent filing with the SEC.

Other large investors have also added to or reduced their stakes in the company. Westpac Banking Corp acquired a new stake in Illumina during the third quarter valued at about $4,870,000. Blue Jay Capital Management LLC acquired a new stake in Illumina during the third quarter valued at about $10,767,000. Nelson Roberts Investment Advisors LLC raised its stake in Illumina by 1.8% in the third quarter. Nelson Roberts Investment Advisors LLC now owns 34,269 shares of the life sciences company’s stock valued at $6,225,000 after buying an additional 594 shares during the last quarter. Viking Global Investors LP acquired a new stake in Illumina during the fourth quarter valued at about $44,810,000. Finally, Atlanta Capital Group raised its stake in Illumina by 34.0% in the third quarter. Atlanta Capital Group now owns 12,285 shares of the life sciences company’s stock valued at $2,232,000 after buying an additional 3,114 shares during the last quarter. 92.79% of the stock is owned by institutional investors.

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Illumina, Inc. (NASDAQ:ILMN) traded down 1.06% on Friday, hitting $175.29. 1,302,599 shares of the stock were exchanged. The company’s 50 day moving average is $169.25 and its 200 day moving average is $152.32. The stock has a market cap of $25.64 billion, a PE ratio of 57.10 and a beta of 0.79. Illumina, Inc. has a 1-year low of $119.37 and a 1-year high of $186.88.

Illumina (NASDAQ:ILMN) last released its earnings results on Tuesday, January 31st. The life sciences company reported $0.85 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.82 by $0.03. Illumina had a net margin of 19.31% and a return on equity of 22.89%. The company had revenue of $619 million for the quarter, compared to the consensus estimate of $612.50 million. During the same period in the prior year, the company posted $0.81 EPS. The company’s revenue was up 4.6% compared to the same quarter last year. On average, equities research analysts expect that Illumina, Inc. will post $3.64 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: This news story was reported by Financial Market News and is the sole property of of Financial Market News. If you are accessing this news story on another domain, it was illegally stolen and republished in violation of international copyright laws. The legal version of this news story can be read at http://www.financial-market-news.com/douglas-lane-associates-llc-has-82-687-million-stake-in-illumina-inc-ilmn/1406210/.

ILMN has been the subject of several recent research reports. CL King raised shares of Illumina from a “neutral” rating to a “buy” rating in a research report on Friday, January 6th. Vetr raised shares of Illumina from a “buy” rating to a “strong-buy” rating and set a $148.34 price objective for the company in a research report on Tuesday, January 3rd. Piper Jaffray Companies reissued an “overweight” rating and issued a $187.00 price objective (up previously from $170.00) on shares of Illumina in a research report on Friday, April 14th. Evercore ISI raised shares of Illumina from a “hold” rating to a “buy” rating and set a $190.00 price objective for the company in a research report on Monday, February 27th. Finally, Cowen and Company reissued an “outperform” rating and issued a $150.00 price objective on shares of Illumina in a research report on Wednesday, January 11th. Three equities research analysts have rated the stock with a sell rating, eleven have given a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus price target of $161.22.

In other Illumina news, Director A Blaine Bowman sold 3,000 shares of the company’s stock in a transaction dated Wednesday, April 12th. The shares were sold at an average price of $172.72, for a total transaction of $518,160.00. Following the transaction, the director now directly owns 18,704 shares in the company, valued at approximately $3,230,554.88. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Daniel Bradbury sold 600 shares of the company’s stock in a transaction dated Friday, April 7th. The shares were sold at an average price of $172.79, for a total transaction of $103,674.00. Following the transaction, the director now owns 17,065 shares in the company, valued at $2,948,661.35. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 12,476 shares of company stock worth $2,078,440. Corporate insiders own 1.60% of the company’s stock.

Illumina Company Profile

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

5 Day Chart for NASDAQ:ILMN

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).

Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.